Apollo Hospitals Enterprise Limited has informed the Exchange regarding a press release dated Jun 30, 2025, titled "AHEL proposes to unlock value through strategic re-organisation, enabling direct listing of its Omni Channel Pharmacy and Digital Health business".
APOLLOHOSP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.6 pts more than Nifty 100 and 4.0 pts more than its Hospital peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Apollo Hospitals' board has approved a composite scheme to carve out its Omni Channel Pharmacy and Digital Health business into a new listed entity (Apollo Healthtech Limited, "NewCo"). The three-step structure involves (1) demerger of the pharmacy and digital health business into NewCo, (2) merger of subsidiary Apollo HealthCo (AHL) into NewCo, and (3) merger of Keimed Private Limited (wholesale pharma distributor) into NewCo. For every 100 shares held in Apollo Hospitals, shareholders will receive 195.2 shares of NewCo, while Apollo Hospitals will retain a 15% stake. The combined NewCo had FY25 revenue of about Rs 16,300 crore (~$1.9 bn), with a target of ~Rs 25,000 crore by FY27 at ~7% EBITDA margin. The scheme is subject to NCLT, SEBI, stock exchanges, IRDA, CCI, shareholder and creditor approvals, and the listing is expected within 18–21 months. Separately, AHL will acquire the remaining 74.5% in Apollo Medicals (AMPL) to take its holding to 100%.
Existing Apollo Hospitals shareholders will get direct shareholding in a focused pharmacy + digital health entity, removing any holding-company discount and enabling fuller value discovery. The core hospital business becomes a sharper pure-play, while the new listed entity gives investors a direct play on India's largest omni-channel pharmacy distribution platform. Stock may see a re-rating, though the restructuring is subject to multiple regulatory approvals and 18–21 months to consummation.